Diagonal Bio AB (DIABIO) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.084x

Based on the latest financial reports, Diagonal Bio AB (DIABIO) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.27 Million ≈ $-244.50K USD) by net assets (Skr26.97 Million ≈ $2.90 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Diagonal Bio AB (DIABIO) total market value for the company's overall valuation and market capitalisation.

Diagonal Bio AB - Cash Flow Conversion Efficiency Trend (2020–2024)

This chart illustrates how Diagonal Bio AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Diagonal Bio AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Diagonal Bio AB ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Diagonal Bio AB to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Premier Miton Group plc LSE:PMI	0.045x
Thunder Power Holdings, Inc. NASDAQ:AIEV	-0.049x
Augmentum Fintech PLC LSE:AUGM	-0.009x
HSS Hire Group PLC LSE:HSS	0.141x
Greencastle Resources Ltd. V:VGN	-0.014x
Darmi Bersaudara Tbk PT JK:KAYU	0.001x
Enlivex Therapeutics Ltd TA:ENLV	-0.131x
Maven Income And Growth Vct 5 Plc LSE:MIG5	-0.005x

Annual Cash Flow Conversion Efficiency for Diagonal Bio AB (2020–2024)

The table below shows the annual cash flow conversion efficiency of Diagonal Bio AB from 2020 to 2024. View Diagonal Bio AB (DIABIO) share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Skr24.59 Million ≈ $2.65 Million	Skr-13.77 Million ≈ $-1.48 Million	-0.560x	-127.33%
2023-12-31	Skr21.25 Million ≈ $2.29 Million	Skr-5.23 Million ≈ $-562.94K	-0.246x	+51.22%
2022-12-31	Skr31.25 Million ≈ $3.36 Million	Skr-15.77 Million ≈ $-1.70 Million	-0.505x	-56.20%
2021-12-31	Skr33.87 Million ≈ $3.64 Million	Skr-10.94 Million ≈ $-1.18 Million	-0.323x	-1367.78%
2020-12-31	Skr8.89 Million ≈ $957.03K	Skr226.67K ≈ $24.39K	0.025x	--

About Diagonal Bio AB

ST:DIABIO Sweden Biotechnology

Market Cap

$703.53K

Skr6.54 Million SEK

Market Cap Rank

#30885 Global

#724 in Sweden

Share Price

Skr0.00

Change (1 day)

+0.00%

52-Week Range

Skr0.00 - Skr0.01

All Time High

Skr11.18